<DOC>
	<DOCNO>NCT01717625</DOCNO>
	<brief_summary>This study multicentered , prospective , randomized , open , parallel , intervention study . The aim study evaluate efficacy safety Montelukast sodium prevention bronchopulmonary dysplasia ( BPD ) preterm infant , 32weeks gestational age . The investigator evaluate first effectiveness morbidity mortality bronchopulmonary dysplasia . And , investigator evaluate second effectiveness oxygen index , usage mechanical ventilator take medicine 2 Weeks , Oxygen Utilization After 4 Weeks , Proinflammatory Cytokine bronchial lavage fluid .</brief_summary>
	<brief_title>The Efficacy Safety Montelukast Sodium Prevention Bronchopulmonary Dysplasia</brief_title>
	<detailed_description />
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Preterm infant bear less 32 week Birth 14 day , oxygen artificial ventilation use patient 20cal/kg/d enteral feed write consent parent congenital anomaly cardiovascular collapse investigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>montelukast</keyword>
	<keyword>BPD</keyword>
	<keyword>singulair</keyword>
	<keyword>prematurity</keyword>
</DOC>